Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NewAmsterdam Pharma N.V.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
August 5, 2026
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2026
Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System
August 4, 2026
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 24, 2026
Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
July 23, 2026
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
July 21, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2026
July 1, 2026
1
2
3
Next Page
→